Health Catalyst (NASDAQ:HCAT – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Risk and Volatility
Health Catalyst has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Valuation and Earnings
This table compares Health Catalyst and Aclarion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $311.14 million | 0.43 | -$177.97 million | ($3.68) | -0.48 |
| Aclarion | $80,000.00 | 88.02 | -$7.23 million | ($7.40) | -0.33 |
Aclarion has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Health Catalyst and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -90.61% | -1.83% | -0.80% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Institutional & Insider Ownership
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Health Catalyst and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 1 | 7 | 3 | 0 | 2.18 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Health Catalyst presently has a consensus price target of $2.45, indicating a potential upside of 38.89%. Aclarion has a consensus price target of $7.50, indicating a potential upside of 206.75%. Given Aclarion’s higher possible upside, analysts clearly believe Aclarion is more favorable than Health Catalyst.
Summary
Health Catalyst beats Aclarion on 10 of the 14 factors compared between the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
